Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson's disease when administered once daily for 28 weeks

Next Previous
Trial Profile

A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson's disease when administered once daily for 28 weeks

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarsasapogenin (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms CONFIDENT-PD
  • Sponsors Phytopharm

Most Recent Events

  • 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
  • 17 Jul 2013 According to a Phytopharm media release, sarsasapogenin did not demonstrate clinical efficacy in this trial. Full results will be published in due course.
  • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top